The Value of RT-CGM to Support Achieving and Maintaining Glycemic Goals
This webinar was recorded on November 7, 2023
Sponsored by Dexcom
Therapeutic inertia is a major obstacle to effective diabetes management. Delaying intensification by one year in type 2 diabetes was associated with substantial clinical and economic burden.1 The American Diabetes Association identifies the use of technology as one way to overcome therapeutic inertia, including the use of continuous glucose monitoring.2
Join our webinar to understand the ways to utilize real-time continuous glucose monitoring (RT-CGM) and overcome barriers for improved glycemic outcomes that may help social determinants of health inequities. We will review the current standards of care and the beneficial evidence of RT-CGM early at diagnosis and when not meeting quality metrics.3 You can also learn how Dexcom Clarity is a useful tool to enable the health care team to monitor glucose information earlier to identify the optimal diabetes care plan.
Zakia Woods McManus, PharmD, CDCES
Quality Coordinator/Ambulatory Care/Population Health Pharmacist
Riverside Health System, Newport News, VA
Ali SN et al. Adv Ther 2020 Feb;37(2)869–882. doi: 10.1007/s12325-019-01199-8.
American Diabetes Association Practice Improvement Resources: https://therapeuticinertia.diabetes.org/practice-improvement-resources, accessed January 21,2022.
American Diabetes Association. Diabetes Care. 2022;45(Suppl1):S97-S112.
This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenter are those of the sponsor or presenter and not of AMCP.